In the latest trading session, 0.44 million 10x Genomics Inc (NASDAQ:TXG) shares changed hands as the company’s beta touched 1.91. With the company’s most recent per share price at $10.88 changed hands at -$0.02 or -0.18% at last look, the market valuation stands at $1.33B. TXG’s current price is a discount, trading about -345.04% off its 52-week high of $48.42. The share price had its 52-week low at $10.80, which suggests the last value was 0.74% up since then.
Analysts gave the 10x Genomics Inc (TXG) stock a consensus recommendation rating of Hold, calculated at a mean rating of 2.47. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 5 recommended TXG as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. 10x Genomics Inc’s EPS for the current quarter is expected to be -0.29.
10x Genomics Inc (NASDAQ:TXG) trade information
Instantly TXG was in red as seen in intraday trades today. With action -11.65%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -24.23%, with the 5-day performance at -11.65% in the red. However, in the 30-day time frame, 10x Genomics Inc (NASDAQ:TXG) is -26.98% down.
The consensus price target for the stock as assigned by Wall Street analysts is 25, meaning bulls need an upside of 56.48% from its recent market value. According to analyst projections, TXG’s forecast low is 24 with 46 as the target high. To hit the forecast high, the stock’s price needs a -322.79% plunge from its current level, while the stock would need to soar -120.59% for it to hit the projected low.
10x Genomics Inc (TXG) estimates and forecasts
Year-over-year growth is forecast to reach 0.30% up from the last financial year.
Consensus estimates given by 15 financial analysts project the company’s revenue in the current quarter to hit an average of 133.55M. 15 analysts are of the opinion that 10x Genomics Inc’s revenue for the current quarter will be 146.4M. The company’s revenue for the corresponding quarters a year ago was 141.01M and 153.1M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -5.29%. The estimates for the next quarter sales put growth at -4.38%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -36.10%. The 2025 estimates are for 10x Genomics Inc earnings to increase by 1.75%, but the outlook for the next 5-year period is at 17.47% per year.
10x Genomics Inc (NASDAQ:TXG)’s Major holders
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 8.5341% or 10.19 million shares worth $198.18 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were ARK ETF Tr-ARK Innovation ETF and Vanguard Total Stock Market Index Fund. With 8.25 shares estimated at $90.6 million under it, the former controlled 7.62% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 3.00% of the shares, roughly 3.25 shares worth around $35.66 million.
